The Food and Drug Administration (FDA) is forecasting a grant opportunity titled "Critical Path Public Private Partnerships Clinical Trials Optional," aimed at supporting the continuation of existing consortia groups established by the Critical Path Institute. The objective of this funding is to maintain and manage these consortia while fostering innovative projects in research, education, and outreach that enhance drug product innovation and accelerate the development of therapeutics. This initiative is part of the Critical Path Initiative, which is crucial for improving the safety, efficacy, quality, and performance of drug products. The grant has an award ceiling and floor of $20 million, with one expected award for fiscal year 2024. Interested applicants can contact Terrin Brown at terrin.brown@fda.hhs.gov or (240) 402-7610 for further information.